Artivion Unveils Promising Clinical Data on Aortic Disease Treatments at STS Annual Meeting Artivion, Inc. recently showcased groundbreaking clinical data from the NEXUS TRIOMPHE and AMDS PERSEVERE trials at the Society of Thoracic Surgeons Annual Meeting, highlighting significant patient outcomes.

Artivion Unveils Promising Clinical Data on Aortic Disease Treatments at STS Annual Meeting #United_States #New_Orleans #Artivion #NEXUS_TRIOMPHE #Aortic_Disease

Artivion to Showcase Innovations at Morgan Stanley Healthcare Conference Artivion is set to participate in the Morgan Stanley 23rd Annual Global Healthcare Conference, addressing advancements in aortic disease treatment.

Artivion to Showcase Innovations at Morgan Stanley Healthcare Conference #USA #healthcare #Atlanta #Artivion #Aortic_Disease

Artivion's Strong Second Quarter 2025 Financial Performance Highlights Significant Growth Artivion, Inc. reported impressive financial results for Q2 2025, showcasing remarkable growth in revenue and net income, alongside major developments in product approval.

Artivion's Strong Second Quarter 2025 Financial Performance Highlights Significant Growth #United_States #Atlanta #financial_results #Artivion #Aortic_Disease

Artivion Set to Engage Investors at Major Upcoming Conferences Artivion, Inc. is gearing up to present at significant investor conferences, focusing on innovations in cardiac surgery related to aortic disease. Don't miss out!

Artivion Set to Engage Investors at Major Upcoming Conferences #USA #Investor_Conferences #Artivion #Atlanta,_Georgia #Aortic_Disease

Artivion Strengthens Financial Position With Successful Exchange of Convertible Notes for Common Stock Artivion, Inc. has successfully closed transactions exchanging $99.5 million in convertible notes for shares, enhancing its financial strength and reducing debt.

Artivion Strengthens Financial Position With Successful Exchange of Convertible Notes for Common Stock #United_States #Atlanta #Convertible_Notes #Artivion #Aortic_Disease

Artivion Pursues Strategic Exchange of $95 Million Convertible Notes for Shares Artivion, Inc. announces a plan to exchange $95 million in convertible notes for common stock, enhancing shareholder value and reducing debt risk.

Artivion Pursues Strategic Exchange of $95 Million Convertible Notes for Shares #USA #Atlanta #Convertible_Notes #Artivion #Aortic_Disease

Artivion Announces Strong Financial Performance for Q1 2025: Revenue Growth and Strategic Advancements In Q1 2025, Artivion reported a revenue increase to $99 million, showing growth against prior year. Notable accomplishments highlight their resilience post-cybersecurity incident.

Artivion Announces Strong Financial Performance for Q1 2025: Revenue Growth and Strategic Advancements #United_States #Atlanta #financial_results #Artivion #Aortic_Disease